{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28","value":"199"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29","value":"265"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Cycle 9"}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"}],"units":"Participants"}],"description":"Cmax of Ramucirumab at the end of ramucirumab infusion.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Docetaxel"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 and Cycle 9, Day 1: Predose, Postdose","title":"Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab","type":"SECONDARY","unitOfMeasure":"microgram/milliliter (μg/mL)"}